Literature DB >> 3521926

Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats.

A Láznícková, M Láznícek, J Kvĕtina, J Drobník.   

Abstract

Plasma protein binding and pharmacokinetic parameters of CHIP (cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV) and CBDCA (cis-diammine-1,1-cyclobutane dicarboxylate platinum II) were investigated in male Wistar rats. The plasma clearance of total and non-protein-bound platinum was determined and compared with that of 99mTc-DTPA. For binding experiments, a novel, simple, and quick method based on adsorption of non-protein-bound platinum species to charcoal was used. The clearance of total platinum after CHIP and CBDCA administration was markedly lower than the glomerular filtration rate (determined as the clearance of 99mTc-DTPA). The renal clearance of non-protein-bound platinum corresponded to 168% and 50% of the glomerular filtration rate for CHIP and CBDCA, respectively. These studies suggested that CHIP was excreted by the rat kidney.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3521926     DOI: 10.1007/bf00306741

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Treatment of intoxication with charcoal hemadsorption.

Authors:  S L Cohan; J F Winchester; M C Gelfand
Journal:  Drug Metab Rev       Date:  1982       Impact factor: 4.518

Review 2.  Cis-diamminedichloroplatinum (II). A new anticancer drug.

Authors:  M Rozencweig; D D von Hoff; M Slavik; F M Muggia
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

3.  Renal handling of cis-diamminedichloroplatinum(II).

Authors:  C Jacobs; S M Kalman; M Tretton; M W Weiner
Journal:  Cancer Treat Rep       Date:  1980

4.  Preparation and metabolism of a cisplatin/serum protein complex.

Authors:  W C Cole; W Wolf
Journal:  Chem Biol Interact       Date:  1980-05       Impact factor: 5.192

5.  Renal toxicity studies of protein-bound platinum(cis).

Authors:  W C Cole; W Wolf
Journal:  Chem Biol Interact       Date:  1981-06       Impact factor: 5.192

6.  Kinetics of cis-dichlorodiammineplatinum.

Authors:  P E Gormley; J M Bull; A F LeRoy; R Cysyk
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

7.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.

Authors:  S J Harland; D R Newell; Z H Siddik; R Chadwick; A H Calvert; K R Harrap
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

8.  Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid.

Authors:  C Jacobs; C N Coleman; L Rich; K Hirst; M W Weiner
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

9.  Mechanisms of renal excretion of cisdichlorodiamine platinum.

Authors:  R Caterson; S Etheredge; P Snitch; G Duggin
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1983-08

10.  o- and M-iodohippurate binding to plasma proteins as a model drug transport mechanism.

Authors:  M Láznícek; J Kvĕtina
Journal:  J Pharm Pharmacol       Date:  1984-10       Impact factor: 3.765

View more
  3 in total

1.  Shape changes induced by N-terminal platination of ubiquitin by cisplatin.

Authors:  Jonathan P Williams; Hazel I A Phillips; Iain Campuzano; Peter J Sadler
Journal:  J Am Soc Mass Spectrom       Date:  2010-02-11       Impact factor: 3.109

2.  In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.

Authors:  R C Gaver; A M George; G Deeb
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Effects of storage on the binding of carboplatin to plasma proteins.

Authors:  K Erkmen; M J Egorin; L M Reyno; R Morgan; J H Doroshow
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.